blue image with words 2021 Q1 synbiobeta market report The synthetic biology industry saw record investment in Q1 2021, signaling up to $36 billion in total investment for 2021.
Home » Entrepreneurship » Q1 Shatters Previous Synthetic Biology Investment Record – Signals Projected 2021 Investment of up to $36 Billion

Q1 Shatters Previous Synthetic Biology Investment Record – Signals Projected 2021 Investment of up to $36 Billion

2021 is shaping up to be a record year for synthetic biology investment. The first quarter of 2021 nearly quadrupled the previous Q1 record set in 2020 and is more than ten-fold higher than Q1 investments from only four years ago. If current funding rates hold for this year, investments into the synthetic biology sector could be more than 200-400% larger than 2020.

Q1 2021 shattered all funding records and could lead to as much as $36 B in investment by year’s end.

In many ways, this year’s record-breaking Q1 is a continuation of the record-setting ~$8 billion that went into the synthetic biology sector in 2020. Many of the investment trends in 2020 were driven by the COVID-19 pandemic. Those investment trends, particularly in therapeutics and life science tools and diagnostics, continued this quarter.

The healthcare industry as a whole is not the only sector seeing increased investment from the global pandemic. The global market impacts of COVID-19 also appear to be driving investment across the synthetic biology space. Q1 saw new trends emerge in synthetic biology food companies and the energy sector. Additionally, the new policies of the Biden administration will likely influence synthetic biology investment throughout the year, particularly in bio-based fuels and climate mitigation technologies.

These market influences raise two key questions:

  • How has the funding environment evolved since the first year of the pandemic?
  •  Which trends can we expect to see as the year continues?

Read SynBioBeta’s full analysis including our look at Q2 2021 and why we project the industry could reach $36 billion in total investment by the end of the year.


Stephanie Wisner

Stephanie Wisner is a science writer, specializing in the interface between science and business. She currently serves as Co-founder and Director of Business Operations at Centivax, and works with ARCH Venture Partners on individual projects. Her first book, The Business of Science, will be published later this year with New Degree Press (Expected 2021).

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to

Job opportunities